The first federal trial on claims tying prescription drug Actos to bladder cancer took a hostile turn after a judge concluded the defendants deliberately deleted key evidence.
U.S. District Judge Rebecca Doherty, citing “grave concerns” about the drug manufacturer’s conduct, sanctioned Takeda Pharmaceutical Co. Ltd. and its affiliates by ordering the jury, which heard opening statements on Feb. 3, be informed that 46 files were missing.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
